Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Lev's Cinryze meets HAE prophylaxis endpoint

LEVP said its Cinryze (formerly C1-INH) met the primary endpoint of a significant reduction in HAE

Read the full 162 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE